Translated Article:
Ranking number one in global cancer mortality, lung cancer was, for a long time, the disease that brought the deepest despair to the medical community. Extending a patient’s life at an inoperable stage was nothing short of a miracle. Paradoxically, the field where the most innovative “Precision Medicine” is being realized today is none other than lung cancer. Out of countless types of cancer, why has this specific field achieved such dazzling evolution? The answer lies in the fierce diversity of the disease, the tenacity of scientists who turned failed drugs into miracles, and the remarkable advancements in DNA decoding technologies.
Sub-classification and Lung Cancer Targeted Therapy: A Heterogeneous Disease
Lung cancer is not a single illness but a collection of highly diverse diseases with different causes and forms. When observing cells under a microscope, they are broadly classified into Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). The primary stage where Lung Cancer Targeted Therapy shines is within Non-Small Cell Lung Cancer.
- Small Cell Lung Cancer (SCLC, Approx. 15%): Characterized by small cell sizes, this type mostly occurs in the central part of the bronchi. The vast majority of patients are heavy smokers. Because the speed of cell division and metastasis is explosive, it has often already spread to other organs by the time it is discovered.
- Non-Small Cell Lung Cancer (NSCLC, Approx. 85%): This is an umbrella term for all other lung cancers excluding SCLC, which is further divided into three main subtypes:
- Adenocarcinoma: The most common form, accounting for 40 to 50% of all lung cancers. It usually occurs at the outer edges of the lungs. The absolute majority of lung cancers occurring in non-smokers and women fall into this category. It is the subtype that benefits the most from medical advancements.
- Squamous Cell Carcinoma: Occurs in the bronchial mucosa in the center of the lungs. It has the strongest causal relationship with smoking, and the proportion of male patients is overwhelmingly high.
- Large Cell Carcinoma: Features large cells that multiply quickly, though its incidence rate is relatively low.
In this way, lung cancer is a completely different disease depending on who gets it and how it develops. This fierce complexity paradoxically became a powerful motivation for the development of treatments designed to strike only specific genes.
Historical Turning Points in Lung Cancer Targeted Therapy
There is a clear medical and historical background as to why Lung Cancer Targeted Therapy achieved such groundbreaking growth compared to other cancers.
1. The Clear Presence of “Driver Mutations”
Lung cancers caused by smoking (Squamous Cell Carcinoma, SCLC) occur when hundreds or thousands of genes are randomly damaged by carcinogens in tobacco smoke. This makes it incredibly difficult to pinpoint a target. Conversely, Adenocarcinoma, which primarily affects non-smokers, presents a different pattern. Rather than complex external factors, cancer is often triggered by the malfunction of a single, crucial gene that commands cell growth.
The medical community calls this fatal, core gene a “Driver Mutation.” While a tangled ball of countless mutations is hard to unravel, a driver mutation acts as a clear, single switch. Adenocarcinoma of the lung is a prime example where these switches (such as EGFR, ALK, ROS1) are distinctly observed.
2. A Miracle Born from Failure: The Dramatic Reversal of Gefitinib (Iressa)
The history of this medical field completely flipped in 2004. The very first candidate drug, ‘Iressa’ (Gefitinib), received conditional approval from the US FDA in 2003. However, in the subsequent large-scale clinical trial (ISEL), it failed to improve the overall survival rate of general Western lung cancer patients. It was on the verge of being withdrawn from the market.
“In 2004, Harvard researchers, including those at the Dana-Farber Cancer Institute, were astounded while re-analyzing the data. In a specific group—Asians, women, non-smokers, and adenocarcinoma patients—the cancer cells melted away like magic.”
The researchers uncovered the historical fact that this responsive group universally shared a mutation in the EGFR (Epidermal Growth Factor Receptor). This discovery shifted the standard of cancer treatment from the organ (the “lung”) to the gene (the “EGFR”). The era of true precision medicine—administering drugs only to patients with specific biomarkers—began right here.
Decoding DNA: How NGS and WGS Enhance Lung Cancer Targeted Therapy
As treatments targeting specific genes were developed one after another, diagnostic technologies capable of rapidly and broadly identifying the exact mutations in a patient’s cancer cells became indispensable. This is where NGS (Next-Generation Sequencing) technology steps in. NGS refers to the “ultra-high-speed decoding technology” itself, which reads numerous DNA fragments simultaneously in parallel.
Recently, WGS (Whole Genome Sequencing) is frequently mentioned; it is the most comprehensive analysis method utilizing this NGS technology.
Related Posting : Top 3 Reasons WGS Precision Diagnosis Revolutionizes Cancer Therapy
- Clinical Targeted NGS Panel (Targeted Sequencing): This is the current standard test performed on lung cancer patients in hospitals. Instead of reading the entire 3 billion pairs of human DNA, it acts as a magnifying glass, focusing only on tens to hundreds of core genes proven to be directly linked to lung cancer development. It saves time and costs, perfectly aligning with the practical goal of immediately prescribing medication.
- WGS (Whole Genome Sequencing): This reads the entire 3 billion base pairs of DNA in cancer cells from start to finish without omission. It analyzes not only the protein-coding regions (Exons) but also the non-coding regions (Introns) whose functions are not yet clearly understood. Because the data is so massive, it is currently inefficient for immediate drug prescription in clinics. However, it is essential for discovering future driver mutations and studying the fundamental causes of cancer.
| Category | Clinical Targeted NGS Panel (Current Standard) | WGS (Whole Genome Sequencing) |
| Analysis Scope | Specific cancer-related genes (Tens to Hundreds) | Entire human genome (3 Billion base pairs) |
| Primary Purpose | Discovering and prescribing actionable treatments | Finding unknown mutations, researching cancer mechanisms |
| Data Size | Small (Allows for quick, clear interpretation by clinicians) | Very Large (Requires extensive bioinformatics analysis) |
| Cost & Time | Relatively affordable and fast (Typically within 2-3 weeks) | Expensive and extremely time-consuming to analyze |
In short, if NGS is an ultra-high-speed scanner, the Targeted NGS Panel is “scanning only the summary,” while WGS is “scanning the entire encyclopedia without missing a page.” Thanks to the evolution of these scanners, medical treatments have advanced at a blinding pace.
Actionable Guidelines for Success with Lung Cancer Targeted Therapy
In the past, a lung cancer diagnosis was akin to a death sentence. Now, however, it has entered the realm of highly advanced tactics—analyzing clear genetic targets and striking them with precision. The specific actionable takeaways that patients and caregivers must follow are:
1. Mandating NGS Panels for Initial Lung Cancer Targeted Therapy
If you are diagnosed with lung cancer through a biopsy, do not settle for a single-gene test (PCR); you must request a comprehensive NGS panel test. You can only deploy the most powerful treatments with the fewest side effects at the right time if you accurately identify the “driver mutations” (EGFR, ALK, ROS1, KRAS, etc.) controlling your cancer cells.
2. Utilizing Re-biopsies to Sustain Lung Cancer Targeted Therapy
Do not despair if your cancer begins to grow again due to drug resistance. This simply means the cancer cells have altered their genetic code to survive. Through a re-biopsy or a liquid biopsy using blood, you must swiftly identify the newly emerged resistance mutation (e.g., T790M) and switch your weapon to a next-generation medication designed to suppress it.
Key Takeaways on Lung Cancer Targeted Therapy
- Lung cancer features highly diverse histological subtypes (Adenocarcinoma, Squamous Cell Carcinoma, etc.), and specialized treatments are most actively utilized for Adenocarcinoma.
- The distinct presence of “driver mutations” in non-smoking adenocarcinoma patients became the crucial foundation for therapeutic drug development.
- The 2004 identification of the EGFR mutation, which reversed the failure of Iressa’s survival rate trials, is a historic event that launched the era of precision medicine.
- Currently, hospitals conduct “Targeted NGS Panel Tests” using NGS technology to quickly analyze only the core genes.
- WGS is a comprehensive test that analyzes the entire genome, acting as the core infrastructure for future drug development and research.